Cargando…

Immune-Related Adverse Events: A Case-Based Approach

Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connolly, Caoilfhionn, Bambhania, Kalindi, Naidoo, Jarushka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598598/ https://www.ncbi.nlm.nih.gov/pubmed/31293970 http://dx.doi.org/10.3389/fonc.2019.00530

Ejemplares similares

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
por: Moseley, Kendall F., et al.
Publicado: (2018)

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
por: Yang, Ruoning, et al.
Publicado: (2022)

Baseline risk factors associated with immune related adverse events and atezolizumab
por: Madjar, Katrin, et al.
Publicado: (2023)

Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis
por: Cui, Jin, et al.
Publicado: (2022)

Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
por: Hou, Wanting, et al.
Publicado: (2021)

Editorial: Immune-related adverse events for patients with lung cancer-volume II
por: Wang, Yusha, et al.
Publicado: (2023)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
por: Chye, Adrian, et al.
Publicado: (2022)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
por: Burke, Michael, et al.
Publicado: (2021)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Park, Robin, et al.
Publicado: (2020)

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
por: Zheng, Xiaohu, et al.
Publicado: (2021)

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
por: Ouyang, Tao, et al.
Publicado: (2021)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
por: Liang, Kai-li, et al.
Publicado: (2022)

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
por: Fan, Yong, et al.
Publicado: (2021)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events
por: Zeng, Yanlin, et al.
Publicado: (2023)

Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
por: McKelvey, Kelly J., et al.
Publicado: (2020)

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
por: Rose, Lynn M., et al.
Publicado: (2021)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials
por: Zheng, Jianqing, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer
por: Wu, Yan, et al.
Publicado: (2022)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Bastacky, Melissa L., et al.
Publicado: (2021)

Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2
por: Ragoonanan, Dristhi, et al.
Publicado: (2021)

Editorial: Gastrointestinal cancer immune response and immune related adverse effects
por: Wen, Ti, et al.
Publicado: (2022)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: O’Brien, Susan M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qv9iv6520k3o8umflvs5phpr14